Program
Bevacizumab
Also written as “bevacizumab”, “bevacizumab [Avastin]” and “Avastin (bevacizumab)”.
Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Hepatocellular, led by 35 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 1217 open or running | phase 4since Jun 20, 2005 | Oct 16, 2002 | Nov 30, 2026phase 3 · NCT03148418 |
| Fresenius Kabi | 60 open or running | phase 3since Sep 19, 2017 | Feb 14, 2014 | none ahead |
| AstraZeneca | 54 open or running | phase 3since Nov 28, 2018 | Nov 28, 2018 | none ahead |
| Outlook Therapeutics | 51 open or running | phase 3since Feb 6, 2019 | Feb 6, 2019 | Dec 2027phase 3 · NCT05112861 |
| Pfizer | 50 open or running | phase 3since Jan 12, 2005 | Jan 12, 2005 | none ahead |
| Otsuka | 40 open or running | phase 3since Jan 29, 2021 | Dec 5, 2007 | none ahead |
| Biocad | 30 open or running | phase 3since Dec 27, 2012 | Dec 27, 2012 | none ahead |
| Innovent Biologics | 30 open or running | phase 3since Oct 23, 2016 | Oct 23, 2016 | none ahead |
| ago-research-gmbh | 20 open or running | phase 3since Apr 16, 2013 | Apr 16, 2013 | none ahead |
| GlaxoSmithKline | 21 open or running | phase 2since Oct 10, 2017 | Oct 10, 2017 | Jun 21, 2027phase 2 · NCT06796907 |
| navifus-corporation | 20 open or running | phase 2since Mar 19, 2024 | Jun 16, 2020 | none ahead |
| oncolytics-biotech | 21 open or running | phase 2since Feb 25, 2026 | Jan 7, 2011 | Aug 30, 2027phase 2 · NCT07446322 |
| ppd-development-lp | 22 open or running | phase 2since Nov 20, 2024 | Nov 20, 2024 | Jul 2028phase 2 · NCT06703073 |
| Sinopharm | 20 open or running | phase 3since Mar 22, 2022 | Oct 21, 2019 | none ahead |
| aryogen-pharmed-co | 10 open or running | phase 3since Sep 18, 2017 | Sep 18, 2017 | none ahead |
| Bio-Thera Solutions | 11 open or running | phase 3since Sep 21, 2023 | Sep 21, 2023 | none ahead |
| bradmer-pharmaceuticals-inc | 10 open or running | phase 2since May 19, 2009 | May 19, 2009 | none ahead |
| centus-biotherapeutics-limited | 10 open or running | phase 3since Jun 3, 2016 | Jun 3, 2016 | none ahead |
| Corcept Therapeutics | 11 open or running | phase 2since Apr 1, 2025 | Apr 1, 2025 | Dec 2027phase 2 · NCT06906341 |
| geron-corporation | 10 open or running | phase 2since Dec 2, 2010 | Dec 2, 2010 | none ahead |
| gradalis-inc | 10 open or running | phase 2since Mar 1, 2012 | Mar 1, 2012 | none ahead |
| iOMEDICO | 10 open or running | phase 4since Aug 28, 2014 | Aug 28, 2014 | none ahead |
| Jeil Pharmaceutical | 11 open or running | phase 2since Jan 12, 2026 | Jan 12, 2026 | Dec 31, 2029phase 2 · NCT07370818 |
| Johnson & Johnson | 10 open or running | phase 2since Jun 12, 2008 | Jun 12, 2008 | none ahead |
| laboratorio-elea-phoenix-s-a | 10 open or running | phase 3since Sep 4, 2018 | Sep 4, 2018 | none ahead |
| Laboratorios Sophia S.A de C.V. | 10 open or running | phase 3since Jan 19, 2022 | Jan 19, 2022 | none ahead |
| laboratorios-richmond-s-a-c-i-f | 10 open or running | phase 1since Apr 15, 2019 | Apr 15, 2019 | none ahead |
| mabscale-llc | 11 open or running | phase 3since Dec 8, 2022 | Dec 8, 2022 | Dec 2026phase 3 · NCT05654454 |
| Merck | 10 open or running | phase 3since Jul 1, 2020 | Jul 1, 2020 | none ahead |
| pharmatech | 10 open or running | phase 2since Oct 1, 2008 | Oct 1, 2008 | none ahead |
| prologue-research-international | 10 open or running | phase 3since Jun 5, 2003 | Jun 5, 2003 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 1since Jul 18, 2022 | Jul 18, 2022 | none ahead |
| sirtex-medical | 10 open or running | phase 3since Aug 13, 2008 | Aug 13, 2008 | none ahead |
| the-emmes-company-llc | 10 open or running | phase 3since Oct 22, 2013 | Oct 22, 2013 | none ahead |
| xoft-inc | 10 open or running | phase 2since Dec 17, 2020 | Dec 17, 2020 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, clovis-oncology-inc, Gilead Sciences, adagene-inc, tempest-therapeutics, nikang-therapeutics-inc, immune-onc-therapeutics, inflarx-gmbh, edesa-biotech-inc, icad-inc, quintiles-inc, fp-clinical-pharma-s-r-l, syngene, wuxi-cds-clinical-research-shanghai-co-ltd, libbs-farmace-utica-ltda and Sanofi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since May 9, 2017.
- Mar 22, 2022Phase 3 study in Non-squamous Non-small-cell Lung CancerSinopharm · NCT05318443 · 512 enrolled · China
- Jul 18, 2022Sino Biopharmaceutical's first study: phase 1 study in Rectal NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05476341 · 98 enrolled · China
- Dec 8, 2022mabscale-llc's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to mabscale-llcmabscale-llc · NCT05654454 · 620 planned · Russian Federation
- Mar 2, 2023Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT05775159 · 294 enrolled · United States, China, Hong Kong and more
- Sep 11, 2023Phase 2 study in Carcinoma, HepatocellularAstraZeneca · NCT06040099 · 58 enrolled · United States
- Sep 21, 2023Bio-Thera Solutions's first study: phase 3 study in Uterine Cervical NeoplasmsNew to Bio-Thera SolutionsBio-Thera Solutions · NCT06123884 · 526 planned · China
- Dec 19, 2023Phase 3 study in Macular DegenerationOutlook Therapeutics · NCT06190093 · 400 enrolled · United States
- Mar 19, 2024Phase 2 study in Glioblastomanavifus-corporation · NCT06329570 · 10 enrolled · United States
- Nov 20, 2024ppd-development-lp's first studies: 2 phase 2 studies in Respiratory Distress SyndromeNew to ppd-development-lpppd-development-lp · NCT06703073, NCT06701656
- Jan 22, 2025Phase 2 study in NeoplasmsGlaxoSmithKline · NCT06796907 · 305 planned · United States, Argentina, Australia and more
- Apr 1, 2025Corcept Therapeutics's first study: phase 2 study in Ovarian NeoplasmsNew to Corcept TherapeuticsCorcept Therapeutics · NCT06906341 · 270 planned · United States, Belgium, France and more
- Jan 12, 2026Jeil Pharmaceutical's first study: phase 2 study in Ovarian NeoplasmsNew to Jeil PharmaceuticalJeil Pharmaceutical · NCT07370818 · 81 planned · South Korea
- Feb 25, 2026Phase 2 study in Ras-mutated Metastatic Colorectal CancerPhase 2 reachedoncolytics-biotech · NCT07446322 · 60 planned · United States
- Nov 16, 2026Primary completion moved from 2026-08 to 2027-12Date moved laterphase 2 · +16 months · NCT06906341
Ahead
- Nov 30, 2026Primary completion: phase 3 study in NeoplasmsHoffmann-La Roche · NCT03148418
- Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell Lungmabscale-llc · NCT05654454
- Jun 21, 2027Primary completion: phase 2 study in NeoplasmsGlaxoSmithKline · NCT06796907
- Jun 30, 2027Primary completion: phase 3 study in NeoplasmsHoffmann-La Roche · NCT05112965
TargetBeta
“A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine”NCIt, by rule
“Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule
Other programs on VEGFA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ranibizumabrule | Novartis | phase 4 | 108 |
| afliberceptrule | Regeneron Pharmaceuticals | phase 4 | 89 |
| faricimabrule | Hoffmann-La Roche | phase 4 | 17 |
| ivonescimabrule | Akeso | phase 3 | 48 |
| pumitamig | BioNTech | phase 3 | 34 |
| tivunatamig | Pfizer | phase 3 | 15 |
| suvemcitugrule | Simcere Pharmaceutical Group | phase 3 | 6 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| surabgene lomparvovec | AbbVie | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| HLX37 | Fosun Pharma | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
Studies
The newest 60 of 185 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07446322Ras-mutated Metastatic Colorectal Cancer · United States | 2 | Recruiting | oncolytics-biotech | Aug 30, 2027 | 60 |
| NCT07370818Ovarian Neoplasms · South Korea | 2 | Not yet recruiting | Jeil Pharmaceutical | Dec 31, 2029 | 81 |
| NCT06906341Ovarian Neoplasms · United States, Belgium, France and more | 2 | Recruiting | Corcept Therapeutics | Dec 2027 | 270 |
| NCT06796907Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | GlaxoSmithKline | Jun 21, 2027 | 305 |
| NCT06703073Respiratory Distress Syndrome · United States | 2 | Recruiting | ppd-development-lp | Jul 2028 | 600 |
| NCT06701656Respiratory Distress Syndrome · United States | 2 | Recruiting | ppd-development-lp | Jul 2028 | 200 |
| NCT06329570Glioblastoma · United States | 2 | Suspended | navifus-corporation | Dec 31, 2027 | 10 |
| NCT06190093Macular Degeneration · United States | 3 | Completed | Outlook Therapeutics | Nov 7, 2024 | 400 |
| NCT06123884Uterine Cervical Neoplasms · China | 3 | Recruiting | Bio-Thera Solutions | Sep 2026 | 526 |
| NCT06040099Carcinoma, Hepatocellular · United States | 2 | Active, not recruiting | AstraZeneca | Jun 30, 2026 | 58 |
| NCT05775159Carcinoma, Hepatocellular · United States, China, Hong Kong and more | 2 | Active, not recruiting | AstraZeneca | Oct 27, 2026 | 294 |
| NCT05654454Carcinoma, Non-Small-Cell Lung · Russian Federation | 3 | Recruiting | mabscale-llc | Dec 2026 | 620 |
| NCT05476341Rectal Neoplasms · China | 1 | Completed | Sino Biopharmaceutical | Aug 18, 2017 | 98 |
| NCT05318443Non-squamous Non-small-cell Lung Cancer · China | 3 | Completed | Sinopharm | Dec 26, 2022 | 512 |
| NCT05217680Diabetic Macular Edema · Mexico | 3 | Completed | Laboratorios Sophia S.A de C.V. | Aug 18, 2025 | 509 |
| NCT05112965Neoplasms · China | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 49 |
| NCT05112861Macular Degeneration · United States | 3 | Active, not recruiting | Outlook Therapeutics | Dec 2027 | 120 |
| NCT04929223Colorectal Neoplasms · United States, Australia, Canada and more | 1 | Recruiting | Hoffmann-La Roche | Aug 31, 2030 | 542 |
| NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Hoffmann-La Roche | Feb 28, 2028 | 176 |
| NCT04737187Colorectal Neoplasms · United States, Austria, Belgium and more | 3 | Completed | Otsuka | Jul 19, 2022 | 492 |
| NCT04732286Carcinoma, Hepatocellular · Spain | 3 | Terminated | Hoffmann-La Roche | Apr 26, 2024 | 100 |
| NCT04681677Glioblastoma · United States | 2 | Terminated | xoft-inc | Apr 24, 2024 | 12 |
| NCT04677504Biliary Tract Neoplasms · United States, China, Hong Kong and more | 2 | Completed | Hoffmann-La Roche | May 16, 2022 | 162 |
| NCT04524871Advanced Liver Cancers · United States, China, France and more | 2 | Active, not recruiting | Hoffmann-La Roche | Jul 30, 2027 | 518 |
| NCT04516278Macular Degeneration · United States | 3 | Completed | Outlook Therapeutics | Feb 10, 2021 | 197 |
| NCT04487067Carcinoma, Hepatocellular · Italy | 3 | Completed | Hoffmann-La Roche | Aug 13, 2024 | 152 |
| NCT04456699Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Completed | Merck | Mar 27, 2023 | 335 |
| NCT04446416Glioblastoma · Taiwan | – | Completed | navifus-corporation | Sep 30, 2022 | 6 |
| NCT04426825Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Hoffmann-La Roche | Jan 19, 2022 | 23 |
| NCT04408989Healthy Volunteers · New Zealand | 1 | Completed | Fresenius Kabi | Aug 20, 2021 | 114 |
| NCT04238663Healthy Volunteers · Germany | 1 | Completed | Fresenius Kabi | Mar 17, 2020 | 115 |
| NCT04238650Healthy Volunteers · Japan | 1 | Completed | Fresenius Kabi | Dec 27, 2019 | 49 |
| NCT04135898Healthy Male · China | 1 | Completed | Sinopharm | Mar 16, 2020 | 88 |
| NCT04325698Advanced Non-squamous NSCLC · China | 3 | Terminated | Pfizer | May 10, 2021 | 8 |
| NCT04126044Pharmacokinetics · China | 1 | Withdrawn | Pfizer | Jul 10, 2021 | 0 |
| NCT04102098Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | Oct 21, 2022 | 668 |
| NCT04091217Melanoma · China | 2 | Completed | Hoffmann-La Roche | Aug 31, 2022 | 43 |
| NCT04068610Colonic Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | AstraZeneca | Oct 10, 2022 | 61 |
| NCT03919448Pharmacokinetics · Argentina | 1 | Completed | laboratorios-richmond-s-a-c-i-f | Sep 11, 2019 | 112 |
| NCT03847428Carcinoma, Hepatocellular · United States, Australia, Austria and more | 3 | Completed | AstraZeneca | May 15, 2026 | 908 |
| NCT03844074Macular Degeneration · Australia | 3 | Completed | Outlook Therapeutics | Jul 23, 2020 | 61 |
| NCT03834753Macular Degeneration · United States | 3 | Completed | Outlook Therapeutics | Jun 7, 2021 | 228 |
| NCT03794440Carcinoma, Hepatocellular · China | 3 | UNKNOWN | Innovent Biologics | Dec 2022 | 595 |
| NCT03778957Carcinoma, Hepatocellular · United States, Australia, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Sep 11, 2023 | 724 |
| NCT03690739Ovarian Neoplasms · Germany | 3 | Terminated | ago-research-gmbh | Mar 3, 2021 | 9 |
| NCT03693573Carcinoma, Renal Cell | 3 | Withdrawn | Hoffmann-La Roche | Aug 14, 2021 | 0 |
| NCT03668054Macular Degeneration · Argentina | 3 | Completed | laboratorio-elea-phoenix-s-a | May 30, 2018 | 22 |
| NCT03635489Ovarian Neoplasms · China | 3 | Completed | Hoffmann-La Roche | May 26, 2021 | 100 |
| NCT03555149Colorectal Neoplasms · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Sep 26, 2022 | 96 |
| NCT03434379Carcinoma, Hepatocellular · United States, Australia, Canada and more | 3 | Completed | Hoffmann-La Roche | Aug 31, 2020 | 558 |
| NCT03424005Breast Neoplasms · United States, Australia, France and more | 2 | Recruiting | Hoffmann-La Roche | Sep 30, 2030 | 1,132 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
| NCT03326193Ovarian Neoplasms · United States | 2 | Completed | GlaxoSmithKline | Dec 24, 2020 | 105 |
| NCT03296163Carcinoma, Non-Small-Cell Lung · Brazil, Bulgaria, Chile and more | 3 | Completed | Fresenius Kabi | Jul 3, 2019 | 627 |
| NCT03288987Colorectal Neoplasms · Iran, Islamic Republic of | 3 | Completed | aryogen-pharmed-co | Jul 30, 2018 | 126 |
| NCT03293654Healthy Volunteers · United Kingdom | 1 | Completed | Fresenius Kabi | May 29, 2019 | 114 |
| NCT03280563Breast Neoplasms · United States, Israel, South Korea | 2 | Completed | Hoffmann-La Roche | Sep 26, 2024 | 144 |
| NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more | 2 | Completed | Hoffmann-La Roche | Feb 27, 2025 | 341 |
| NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 1,000 |
| NCT03148418Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Nov 30, 2026 | 382 |
How it is read
Names in the registry
- “Bevacizumab”, 133 entries
- “bevacizumab”, 31 entries
- “bevacizumab [Avastin]”, 20 entries
- “Avastin (bevacizumab)”, 6 entries
- “Utidelone combined with Bevacizumab”, 3 entries
Codes read as this program: MB02.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 51 studies
- Carcinoma, Non-Small-Cell Lung, 34 studies
- Breast Neoplasms, 27 studies
- Ovarian Neoplasms, 26 studies
- Carcinoma, Hepatocellular, 13 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.